down arrow

DaVita, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US23918K1088
USD
117.28
-0.97 (-0.82%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

116.39118.50

52 Week

113.97179.60
Valuation
Technical
Day's Volume

CASH

660.85 k

Shareholding (Mar 2025)

FII

11.20%

Held by 317 FIIs

DII

68.31%

Held by 31 DIIs

Promoter

0.01%

How big is DaVita, Inc.?

22-Jun-2025

As of Jun 18, DaVita, Inc. has a market capitalization of $11.36 billion, with net sales of $12.97 billion and a net profit of $1.18 billion for the latest four quarters. The balance sheet shows shareholder's funds of $121.12 million and total assets of $17.97 billion.

As of Jun 18, DaVita, Inc. has a market capitalization of 11,364.46 million, categorizing it as a Mid Cap company.<BR><BR>As of Jun 18, the company reported net sales of 12,968.52 million and a net profit of 1,176.98 million for the latest four quarters.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 121.12 million and total assets of 17,971.92 million.

Read More

What does DaVita, Inc. do?

22-Jun-2025

DaVita, Inc. provides kidney dialysis services for chronic kidney failure patients and has a market capitalization of approximately $11.36 billion. As of March 2025, it reported net sales of $3.22 billion and a net profit of $232 million.

Overview:<BR>DaVita, Inc. operates in the Pharmaceuticals & Biotechnology industry, providing kidney dialysis services for patients suffering from chronic kidney failure, with a market capitalization in the mid-cap bracket.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 3,224 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: 232 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 11,364.46 Million (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 10.00<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -35.01<BR>- Return on Equity: -423.09%<BR>- Price to Book: -42.55<BR><BR>Contact Details:<BR>- Address: 2000 16th St, DENVER CO: 80202-5158<BR>- Tel: ['1 310 5362668', '1 310 5362585']<BR>- Fax: 1 302 6365454<BR>- Website: https://www.davita.com/

Read More

Who are in the management team of DaVita, Inc.?

22-Jun-2025

As of March 2022, DaVita, Inc.'s management team includes CEO Javier Rodriguez and several independent directors, including Pamela Arway (Chair), Charles Berg, Shawn Guertin, Barbara Desoer, Paul Diaz, and John Nehra.

As of March 2022, the management team of DaVita, Inc. includes the following individuals:<BR><BR>- Ms. Pamela Arway, who serves as the Independent Chairman of the Board.<BR>- Mr. Javier Rodriguez, who is the Chief Executive Officer and a Director.<BR>- Mr. Charles Berg, who is a Director.<BR>- Mr. Shawn Guertin, who is also a Director.<BR>- Ms. Barbara Desoer, who holds the position of Independent Director.<BR>- Mr. Paul Diaz, who is an Independent Director.<BR>- Mr. John Nehra, who is another Independent Director.<BR><BR>In summary, the management team consists of a mix of independent directors and key executives, with Mr. Javier Rodriguez as the CEO.

Read More

Is DaVita, Inc. overvalued or undervalued?

20-Sep-2025

As of May 12, 2025, DaVita, Inc. is considered risky and overvalued with a P/E ratio of 10, an EV to EBITDA ratio of 7.83, and poor performance compared to peers and the S&P 500, indicating a negative investment outlook.

As of 12 May 2025, the valuation grade for DaVita, Inc. has moved from attractive to risky, indicating a shift towards a more negative outlook. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 10, an EV to EBITDA ratio of 7.83, and a PEG ratio of 0.75, which suggests that despite a low P/E, the overall valuation does not support a favorable investment case given the risks involved.<BR><BR>In comparison to its peers, DaVita's P/E ratio of 9.71 is significantly lower than Encompass Health Corp. at 20.94 and The Ensign Group, Inc. at 32.46, both of which are rated attractive. Additionally, the company's return performance has lagged behind the S&P 500, with a year-to-date return of -12.92% compared to the index's 12.22%, and a one-year return of -20.18% versus 17.14%. This underperformance reinforces the notion that DaVita, Inc. is currently overvalued in the market.

Read More

Is DaVita, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, DaVita, Inc. exhibits a bearish technical trend, with negative performance indicators and year-to-date returns of -12.92%, significantly underperforming the S&P 500.

As of 10 September 2025, the technical trend for DaVita, Inc. has changed from mildly bearish to bearish. The weekly MACD is bearish, and the daily moving averages also indicate a bearish stance. Bollinger Bands confirm a bearish trend on both weekly and monthly time frames. The KST shows a mildly bullish signal on the weekly but is mildly bearish on the monthly, while the Dow Theory indicates a mildly bearish trend on the weekly with no trend on the monthly. The OBV is mildly bearish across both time frames.<BR><BR>In terms of performance, DaVita has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -12.92% versus the S&P 500's 12.22%, and a one-year return of -20.18% compared to the S&P 500's 17.14%. Overall, the current technical stance is bearish, reflecting weakness in the indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Operating profit has grown by an annual rate 2.01% of over the last 5 years
  • High Debt Company with a Debt to Equity ratio (avg) at times
2

Negative results in Jun 25

3

Risky - Negative Book Value

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 10,660 Million (Small Cap)

stock-summary
P/E

10.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-26.14

stock-summary
Return on Equity

-296.97%

stock-summary
Price to Book

-28.84

Revenue and Profits:
Net Sales:
3,380 Million
(Quarterly Results - Jun 2025)
Net Profit:
275 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-13.48%
0%
-13.48%
6 Months
-14.24%
0%
-14.24%
1 Year
-28.22%
0%
-28.22%
2 Years
10.03%
0%
10.03%
3 Years
57.76%
0%
57.76%
4 Years
18.66%
0%
18.66%
5 Years
7.3%
0%
7.3%

DaVita, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
DaVita, Inc. Hits New 52-Week Low at USD 117.73

DaVita, Inc. Hits New 52-Week Low at USD 117.73

DaVita, Inc. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company, with a market capitalization of approximately USD 10.66 billion, faces financial challenges, including a negative book value and a high debt-to-equity ratio, raising concerns about its market position.

Read More
DaVita, Inc. Hits 52-Week Low at USD 122.92 Amid Financial Struggles

DaVita, Inc. Hits 52-Week Low at USD 122.92 Amid Financial Struggles

DaVita, Inc. has hit a new 52-week low, reflecting a notable decline in its stock price over the past year. The company faces financial challenges, including a negative book value and a high debt-to-equity ratio, despite a modest growth rate in operating profit over the last five years.

Read More
DaVita, Inc. Stock Plummets to New 52-Week Low of $123.15

DaVita, Inc. Stock Plummets to New 52-Week Low of $123.15

DaVita, Inc. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company faces financial challenges, including a negative book value and a high debt-to-equity ratio. Its performance has lagged behind broader market trends, indicating ongoing difficulties.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
2.69%
EBIT Growth (5y)
2.01%
EBIT to Interest (avg)
4.56
Debt to EBITDA (avg)
3.65
Net Debt to Equity (avg)
-35.01
Sales to Capital Employed (avg)
1.26
Tax Ratio
18.55%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
93.70%
ROCE (avg)
17.82%
ROE (avg)
106.77%
Valuation key factors
Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
-42.98
EV to EBIT
10.70
EV to EBITDA
7.83
EV to Capital Employed
2.29
EV to Sales
1.61
PEG Ratio
0.75
Dividend Yield
NA
ROCE (Latest)
21.42%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 115 Schemes (20.47%)

Foreign Institutions

Held by 317 Foreign Institutions (11.2%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 4.84% vs -2.16% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 18.52% vs -33.51% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3,379.50",
          "val2": "3,223.50",
          "chgp": "4.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "705.20",
          "val2": "609.80",
          "chgp": "15.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "144.00",
          "val2": "133.00",
          "chgp": "8.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "275.20",
          "val2": "232.20",
          "chgp": "18.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "157.00%",
          "val2": "134.40%",
          "chgp": "2.26%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 5.56% vs 4.57% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 30.69% vs 24.58% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "12,815.50",
          "val2": "12,140.10",
          "chgp": "5.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2,678.70",
          "val2": "2,346.40",
          "chgp": "14.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "412.30",
          "val2": "295.00",
          "chgp": "39.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "89.70",
          "val2": "-22.90",
          "chgp": "491.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,250.70",
          "val2": "957.00",
          "chgp": "30.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "152.50%",
          "val2": "131.90%",
          "chgp": "2.06%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
3,379.50
3,223.50
4.84%
Operating Profit (PBDIT) excl Other Income
705.20
609.80
15.64%
Interest
144.00
133.00
8.27%
Exceptional Items
0.00
0.00
Consolidate Net Profit
275.20
232.20
18.52%
Operating Profit Margin (Excl OI)
157.00%
134.40%
2.26%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 4.84% vs -2.16% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 18.52% vs -33.51% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
12,815.50
12,140.10
5.56%
Operating Profit (PBDIT) excl Other Income
2,678.70
2,346.40
14.16%
Interest
412.30
295.00
39.76%
Exceptional Items
89.70
-22.90
491.70%
Consolidate Net Profit
1,250.70
957.00
30.69%
Operating Profit Margin (Excl OI)
152.50%
131.90%
2.06%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 5.56% vs 4.57% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 30.69% vs 24.58% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About DaVita, Inc. stock-summary
stock-summary
DaVita, Inc.
Pharmaceuticals & Biotechnology
DaVita Inc., formerly DaVita HealthCare Partners Inc., operates one division: DaVita Kidney Care (Kidney Care). The Kidney Care division consists of the Company's United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support. The Company's segments include U.S. dialysis and related lab services and Other-Ancillary services and strategic initiatives. Its U.S. dialysis and related lab services line of business provide kidney dialysis services in the United States for patients suffering from chronic kidney failure, also known as an end-stage renal disease (ESRD). In addition, as of March 31, 2019, the Company operated or provided administrative services to 243 outpatient dialysis centers located in nine countries outside of the United States.
Company Coordinates stock-summary
Company Details
2000 16th St , DENVER CO : 80202-5158
stock-summary
Tel: 1 310 53626681 310 5362585
stock-summary
https://www.davita.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."